Curaleaf Improves Takeover Offer For Aurora Cannabis
Curaleaf (CURA) raised its takeover bid for Aurora Cannabis (ACB) to $5 per share, a 28% premium over ACB's Oct. 2 closing price. The offer includes 0.4013 CURA shares plus $1 in cash. Curaleaf aims to combine the businesses, while Aurora urges shareholders to reject the bid, calling it undervalued.
How this was made

The 30-second read
Why it matters
The increased bid heightens the likelihood of a deal but also intensifies shareholder resistance, creating divergent price pressures for both companies.
Market read
The announcement is a primary M&A disclosure with immediate trading implications for both CURA and ACB.
What to watch
Regulatory approvals and financing capacity for Curaleaf could delay or derail the transaction.
Background
Curaleaf, a U.S. cannabis operator, is pursuing a hostile takeover of Canadian peer Aurora Cannabis, raising its offer to $5 per share.
Ticker impact
Aurora Cannabis received a revised $5 per share hostile takeover proposal from Curaleaf, up from $4 per share.
likely downward pressure as market prices in the hostile takeover risk and valuation concerns
The higher premium still leaves Aurora shareholders dissatisfied, prompting sell‑side pressure.
Market effects
The cannabis sector may see heightened M&A activity and valuation scrutiny.
North American cannabis stocks could experience volatility as the deal unfolds.
Limited to investors focused on the cannabis industry and related ETFs.
Counterpoint
If the bid fails, Aurora could rally on a perceived undervaluation, while Curaleaf may face dilution concerns.
Key entities
- CompanyCuraleaf Holdings
U.S.-based cannabis operator offering the takeover.
- CompanyAurora Cannabis
Canadian cannabis producer targeted by the bid.

